ArticleAlimentary pharmacology & therapeutics2026
A Population-Based Matched Cohort Study of Extra-Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease.
Article in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- IBD-related inflammatory memory and colorectal cancer: epigenetic mechanisms and microbiome interventions.Frontiers in immunology · 2026Pooled it
- Comment on "Risk of extraintestinal cancer in patients with inflammatory bowel disease: a multicenter retrospective cohort study in Japan".Journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundTrends in extra-digestive (ED) cancer incidence and mortality in inflammatory bowel diseases (IBD) may be changing with newer approaches to management.
aimsTo study temporal trends and contemporary risks of ED cancers in individuals with and without IBD.
methodsUsing population-level administrative data from Ontario, Canada, we studied ED cancer rates among individuals with IBD and age-sex-matched controls (1:10) without IBD between 1994 and 2020. We modelled age-sex-standardised annual cancer incidence (per 100,000 person-years) over time by first-order linear autoregression, and standardised cancer incidence and mortality rate ratios (SIR, SMR) by quasi-Poisson regression.
resultsThe average annual percentage change (AAPC) in ED cancer incidence was stable among 110,919 people with IBD (0.108%/year; 95% CI, -0.380, 0.599) but declined among 1,109,190 matched controls (-1.39%/year; 95% CI, -1.57, -1.21). Among those with IBD, AAPC was significant for non-Hodgkin's lymphoma (1.48%/year; 95% CI, 0.161, 2.82), melanoma (1.77%/year; 95% CI, 0.781, 2.77), cervical (2.31%/year; 95% CI, 0.602, 4.10), uterine (4.41%/year; 95% CI, 0.045, 8.96) and thyroid (8.10%/year; 95% CI, 4.31, 12.0) cancers, and statistically greater than controls for cervical, ovarian, lung, and bladder cancers. During 2010-2020, ED cancer incidence was higher in those with IBD (SIR 1.20; 95% CI 1.15, 1.26), while ED cancer-related mortality was specifically higher in those with Crohn's disease (CD; SMR 1.31; 95% CI 1.14, 1.51), as compared to matched controls.
conclusionsED cancer incidence has not changed among those with IBD but has declined among matched controls. Beyond 2010, ED cancer incidence is higher among those with IBD and cancer-related mortality is higher among those with CD, relative to matched controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.